Isaac Bruce interviews David Mitchell, President of Mitchell Pharmaceutical Consulting, about bioanalysis regulatory issues, the scientists that have helped to sculpt his career and the future plans for the AAPS.
This article strives to demonstrate that the bioanalytical data obtained in those old days were not qualitatively inferior, but to some extent were superior to the data obtained in contemporary bioanalysis.
Anxiety can be fruitful as a tool for quality improvement. However, it must not supersede sound science. There needs to be clarity in terms of the validation of bioanalytical quantitative data.
This editorial highlights the requirement to combine data, in order to exploit the benefits of integrated biomarker discovery.
Thomas Payne interviews Chris Molloy, IDBS, about software solutions for pharma R&D.
This foreword is for the special focus issue e-solutions in bioanalysis, published in Bioanalysis 3(13).
This article outlines the significance of incurred sample reanalysis and suggests the Bland–Altman plot/tolerance intervals as a means to evaluate method performance.